Graviton BioScience Stock
HealthTechLooking to sell Graviton BioScience stock or options?
Graviton BioScience is a developer of clinical-stage drugs aimed at treating autoimmune disorders, cancer, and other severe diseases. The company's platform is focused on designing and advancing therapeutics for CNS, autoimmune, fibrotic, and various serious conditions where ROCK2 and its other compounds are crucial in disease pathology. Graviton BioScience offers drug candidates targeting Rho-associated protein kinase, a significant mediator of cellular contractility and fibrosis. This enables customers to potentially access revolutionary treatments for a variety of debilitating illnesses.
Pontifax Venture Capital, Ovid Therapeutics, Cormorant Asset Management, Enavate Sciences.
Collective explained in 2 minutes
Learn how Collective's solutions enable you to manage your risk and maximize your wealth
Our available services for this company
Management Team
Board Members
Graviton BioScience’s stock FAQs
Graviton BioScience is currently a private company. This means that the company is not listed on any public exchange and so there is no public market for its stock. However, there may still be ways to monetize Graviton BioScience stock. Depending on Graviton BioScience’s policies, you may be able to: (1) find a private buyer in the secondary market to purchase your stock, (2) borrow against your stock, or (3) exchange Graviton BioScience stock into the Collective Exchange Fund for a limited partnership interest and then borrow non-recourse against your interest to generate immediate cash. This last alternative can be much quicker and net you more after-tax cash than your other options. An exchange into our fund also reduces your risk by diversifying your holdings out of an over-concentrated position.
Collective Liquidity can provide liquidity to shareholders of Graviton BioScience stock in two ways. First, Graviton BioScience employees can exchange shares into the Collective Exchange Fund and then borrow non-recourse to generate immediate cash. This can net you more after-tax cash than a stock sale. It also reduces your risk by diversifying your holdings out of an over-concentrated position. In some cases, Collective may also be able to purchase your Graviton BioScience stock. Note that all transactions in Graviton BioScience shares are subject to the company’s policies regarding secondary transactions. Schedule a call with a Collective Liquidity representative to learn more about your private market liquidity alternatives.
Graviton BioScience stock is not listed on any public exchange and so there is no public market for its shares. Therefore, there is no single, centralized price for Graviton BioScience stock. Typically, shares of private companies like Graviton BioScience are set with buyers in one off negotiations. Collective Liquidity, however, uses a proprietary algorithm to determine its bids so we almost always have an immediately actionable price for you.
On Feb 2024, Graviton BioScience is reported to have closed an equity financing in which the investors valued the company at $252M. This valuation is typically calculated by multiplying the per share price of the preferred stock sold in the financing by the number of Graviton BioScience shares outstanding assuming the conversion of all stock options, warrants, etc.
Tickers are used to identify company’s shares on public markets like the NYSE or Nasdaq. Because Graviton BioScience is not currently publicly traded, it does not have a ticker symbol.
Graviton BioScience has not yet conducted an initial public offering (“IPO”) and so remains a private company. Though Graviton BioScience is a well-known, successful company, there can be no assurance that it will ever go public or be sold. Because of the risk this imposes on Graviton BioScience shareholders, many investors elect to gain liquidity for at least some of their shares before the IPO. Schedule a call with a Collective Liquidity representative to discuss your private market liquidity alternatives.
